Outcomes13

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 13 of 13

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Subjects in Each Group Who Have Achieved an Optimal Mean Blood Pressure Value at 24 Hours of Life	24 hours of life	This outcome is only reportable in the two treatment groups as it evaluates the response to treatment of hypotension in those who received study drug. The comparison group infants were not hypotensive within the 24 hours and did not receive study drug, therefore, they are omitted from this outcome measure.	participants	NUMBER
SECONDARY	Heart Rate Change From Baseline	96 hours or until hypotension completely resolved and medications stopped	This outcome is only reportable in the two treatment groups as it evaluates the change in heart rate in those who received study drug. The comparison group infants were not hypotensive within the 24 hours and did not receive study drug, therefore, they are omitted from this outcome measure.	beats per minute	MEAN
SECONDARY	Acid-base Status	96 hours or until hypotension resolved and medication completely stopped	Treatment groups during study drug administration. Comparison group during first 96 hours of life. For all- only arterial gases	pH	MEAN
SECONDARY	Hyponatremia	96 hours or until medication completely stopped		participants	NUMBER
SECONDARY	Urine Output	96 hours or until hypotension resolved and medication completely stopped		ml/kg/hr	MEAN
SECONDARY	Evidence of Ischemic Changes	96 hours or until medication completely stopped		participants	NUMBER
SECONDARY	Necrotizing Enterocolitis	until hospital discharge, up to 12 weeks		participants	NUMBER
SECONDARY	Ventilator Days	Until hospital discharge, up to 15 months		days	MEDIAN
SECONDARY	Presence of Patent Ductus Arteriosus (PDA)	until hospital discharge, up to 12 weeks		participants	NUMBER
SECONDARY	Grade 3 Intraventricular Hemorrhage or Worse on Head Ultrasound	Until hospital discharge, up to 15 months		participants	NUMBER
SECONDARY	Retinopathy of Prematurity Stage 3 or Higher	Until hospital discharge, up to 15 months		participants	NUMBER
SECONDARY	Presence of Bronchopulmonary Dysplasia (BPD)	36 weeks postmenstrual age		participants	NUMBER
SECONDARY	All Cause Mortality	admission to hospital discharge, up to 15 months		participants	NUMBER

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01318278/outcomes

API reference For AI assistants